Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raloxifene Hydrochloride

FDA-approved product (tablet, oral), marketed as Evista, Raloxifene Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Raloxifene Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Osteoporosis
  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raloxifene Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raloxifene Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

    NCT01573637 · start 2011-07

    Registered record
    Registry ID
    NCT01573637
    Conditions
    Schizophrenia in Post Menopausal Women
    Interventions
    Raloxifene; Lactosa (placebo arm)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-07
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia in Post Menopausal Women
    InterventionRaloxifene; Lactosa (placebo arm)
    PhasePhase 3
    Registry statusCompleted

  • Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

    NCT02354001 · start 2011-04

    Registered record
    Registry ID
    NCT02354001
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Raloxifene hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-04
    Completion
    2019-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionRaloxifene hydrochloride; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder

    NCT01280305 · start 2011-03

    Registered record
    Registry ID
    NCT01280305
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    raloxifene; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-03
    Completion
    2013-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventionraloxifene; placebo
    PhasePhase 3
    Registry statusUnknown

  • Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

    NCT01166958 · start 2010-09

    Registered record
    Registry ID
    NCT01166958
    Conditions
    Osteoporosis
    Interventions
    Teriparatide; Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionTeriparatide; Raloxifene
    PhasePhase 4
    Registry statusCompleted

  • Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

    NCT01077817 · start 2010-02-26

    Registered record
    Registry ID
    NCT01077817
    Conditions
    Esophageal Cancer; Squamous Cell Carcinoma; Adenocarcinoma
    Interventions
    Alendronate; Etidronate; Ibandronate; Risedronate; Raloxifene
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-02-26
    Completion
    2012-02-16
    Enrolment
    684,815

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer; Squamous Cell Carcinoma; Adenocarcinoma
    InterventionAlendronate; Etidronate; Ibandronate; Risedronate +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

    NCT01050842 · start 2010-02

    Registered record
    Registry ID
    NCT01050842
    Conditions
    Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    bicalutamide; raloxifene; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-10-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer
    Interventionbicalutamide; raloxifene; quality-of-life assessment
    PhaseEarly phase 1
    Registry statusCompleted

  • Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

    NCT00847821 · start 2009-05

    Registered record
    Registry ID
    NCT00847821
    Conditions
    Postmenopause
    Interventions
    Bazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg; Bazedoxifene 20 mg/CE 0.45 mg; Bazedoxifene 40 mg/CE 0.45 mg; Raloxifene 60 mg; Placebo
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2009-05
    Completion
    2010-08
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    InterventionBazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg +4 more
    PhaseNot recorded
    Registry statusTerminated

  • Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

    NCT00723398 · start 2009-03

    Registered record
    Registry ID
    NCT00723398
    Conditions
    Breast Cancer
    Interventions
    Lovaza 4gm oral; Raloxifene 60 Mg Oral Tablet; Raloxifene 30 Mg Oral Tablet; Lovaza 4gm & Raloxifene 30mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-03
    Completion
    2015-04
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionLovaza 4gm oral; Raloxifene 60 Mg Oral Tablet; Raloxifene 30 Mg Oral Tablet; Lovaza 4gm & Raloxifene 30mg
    PhaseNot applicable
    Registry statusCompleted

  • Study Evaluating Changes In Mammographic Breast Density

    NCT00774267 · start 2009-01

    Registered record
    Registry ID
    NCT00774267
    Conditions
    Osteoporosis
    Interventions
    BZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; Placebo
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-04
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; Placebo
    PhaseNot recorded
    Registry statusCompleted

  • Back Pain in Patients With Severe Osteoporosis

    NCT00761332 · start 2008-02

    Registered record
    Registry ID
    NCT00761332
    Conditions
    Osteoporosis
    Interventions
    teriparatide; antiresorptives
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-12
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    Interventionteriparatide; antiresorptives
    PhaseNot recorded
    Registry statusCompleted

  • Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

    NCT00431444 · start 2007-01

    Registered record
    Registry ID
    NCT00431444
    Conditions
    Osteoporosis
    Interventions
    Raloxifene; Zoledronic acid; Placebo oral pills; Placebo intravenous (i.v.) infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-07
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionRaloxifene; Zoledronic acid; Placebo oral pills; Placebo intravenous (i.v.) infusion
    PhasePhase 4
    Registry statusCompleted

  • Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

    NCT00371956 · start 2006-09

    Registered record
    Registry ID
    NCT00371956
    Conditions
    Osteoporosis
    Interventions
    raloxifene; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2010-02
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    Interventionraloxifene; placebo
    PhasePhase 4
    Registry statusCompleted

  • Raloxifene for Women With Alzheimer's Disease

    NCT00368459 · start 2006-08

    Registered record
    Registry ID
    NCT00368459
    Conditions
    Alzheimer Disease
    Interventions
    raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2012-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventionraloxifene; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effects of Teriparatide in Postmenopausal Women With Osteoporosis

    NCT00079924 · start 2004-11

    Registered record
    Registry ID
    NCT00079924
    Conditions
    Postmenopausal Osteoporosis
    Interventions
    teriparatide; aldrenodate; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2007-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopausal Osteoporosis
    Interventionteriparatide; aldrenodate; raloxifene
    PhasePhase 4
    Registry statusCompleted

  • Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

    NCT00790101 · start 2004-06

    Registered record
    Registry ID
    NCT00790101
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    Risedronate; Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-06
    Completion
    2004-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionRisedronate; Raloxifene; Placebo
    PhasePhase 4
    Registry statusTerminated